This company listing is no longer active
8IY Stock Overview
Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Yumanity Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.47 |
| 52 Week High | US$3.10 |
| 52 Week Low | US$0.88 |
| Beta | 0 |
| 1 Month Change | -13.53% |
| 3 Month Change | -10.91% |
| 1 Year Change | -47.87% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -92.02% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8IY | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -21.8% | 1.8% | 1.1% |
| 1Y | -47.9% | -23.5% | 1.9% |
Return vs Industry: 8IY underperformed the German Biotechs industry which returned 4.7% over the past year.
Return vs Market: 8IY underperformed the German Market which returned -19.2% over the past year.
Price Volatility
| 8IY volatility | |
|---|---|
| 8IY Average Weekly Movement | 8.9% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 8IY's share price has been volatile over the past 3 months.
Volatility Over Time: 8IY's weekly volatility has decreased from 15% to 9% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 41 | Richard Peters | www.yumanity.com |
Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. The company focuses on discovering disease-modifying therapies to treat neurodegenerative diseases, including Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration. Its lead program is YTX-7739, a novel small molecule that is in Phase I clinical trial for the treatment of Parkinson’s disease and related disorders of a-synuclein.
Yumanity Therapeutics, Inc. Fundamentals Summary
| 8IY fundamental statistics | |
|---|---|
| Market cap | €135.42m |
| Earnings (TTM) | -€30.17m |
| Revenue (TTM) | €4.57m |
29.7x
P/S Ratio-4.5x
P/E RatioIs 8IY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8IY income statement (TTM) | |
|---|---|
| Revenue | US$4.84m |
| Cost of Revenue | US$12.45m |
| Gross Profit | -US$7.60m |
| Other Expenses | US$24.40m |
| Earnings | -US$32.00m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.95 |
| Gross Margin | -156.97% |
| Net Profit Margin | -660.75% |
| Debt/Equity Ratio | 0% |
How did 8IY perform over the long term?
See historical performance and comparison